Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | EYA2 | O00167 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.42 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483430 | 0.89 | ALDH1A1 (0.54) | KMT2AMEN1EHMT2EHMT1APOBEC3G | |
| SCHEMBL10126446 | 0.84 | POLB (0.45) | KMT2AMEN1EHMT2EHMT1APOBEC3G | |
| SCHEMBL3024916 | 0.83 | NPC1 (0.61) | KMT2AMEN1EHMT2EHMT1APOBEC3G | |
| SCHEMBL5095511 | 0.83 | ALDH1A1 (0.50) | KMT2AEHMT2EHMT1APOBEC3GCYP1A2 | |
| SCHEMBL6937212 | 0.83 | TLR7 (0.49) | KMT2AMEN1EHMT2EHMT1APOBEC3G | |
| SCHEMBL15315498 | 0.79 | MEN1 (0.45) | KMT2AMEN1CYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL2259597 | 0.79 | POLB (0.55) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL3821901 | 0.79 | SMARCA2 (0.43) | KMT2AMEN1EHMT2EHMT1APOBEC3G | |
| SCHEMBL3822586 | 0.79 | CA1 (0.46) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL6511271 | 0.79 | POLB (0.41) | KMT2AMEN1EHMT2EHMT1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317009-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| US-7153854-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060270678-A1 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1581535-A1 | PYRROLOPYRIDAZINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-20050075342-A1 | Pyrrolopyridazine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-07 | — | — | US | disclosed |
| US-6849730-B2 | Methods of making porphyrins and related compounds with Lewis acids | NORTH CAROLINA STATE UNIVERSITY (US) | 2005-02-01 | — | — | US | disclosed |
| WO-2004063197-A1 | PYRROLOPYRIDAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
| US-20030096978-A1 | Methods of making porphyrins and related compounds with Lewis acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-22 | — | — | US | disclosed |
| WO-2003027066-A2 | METHODS OF MAKING PORPHYRINS AND RELATED COMPOUNDS WITH LEWIS ACID | NORTH CAROLINA STATE UNIVERSITY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075342-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | KMT2A 3174/4885MEN1 3215/4885EHMT2 3497/4885 |
| US-20060270678-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | KMT2A 3174/4885MEN1 3215/4885EHMT2 3497/4885 |
| US-20030096978-A1 | Methods of making porphyrins and related compounds with Lewis acids | DDT, LIG3, SHARPIN | KMT2A 1351/4885MEN1 118/4885EHMT2 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.